Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mylan has waived its exclusive rights to generic Kaletra (lopinavir / ritonavir) in the US to aid wider access in case the medication would be effective Covid-19 therapies.

The waiver will enable other generics to be eligible for the US Food and Drug Administration (FDA) approval for treating patients in the country, to expand availability when additional clinical trials or other evaluations demonstrate that the product could be an effective Covid-19 treatment.

Last week, Mylan announced the restart of manufacture of hydroxychloroquine sulfate tablets at its facility in the US to cater to demand that could result if the product is proven effective in treating Covid-19.

The company currently holds approval for hydroxychloroquine sulfate to treat malaria, lupus erythematosus and rheumatoid arthritis, now being evaluated to treat the novel coronavirus infection.

Covid-19 therapies: Gilead rescinds remdesivir’s orphan drug designation

Gilead Sciences has requested the FDA to rescind the orphan drug designation awarded for the investigational antiviral drug remdesivir in Covid-19 indication.

The company is also waiving all benefits associated with the designation.

In a statement, Gilead said: “Gilead is confident that it can maintain an expedited timeline in seeking regulatory review of remdesivir, without the orphan drug designation.

“Recent engagement with regulatory agencies has demonstrated that submissions and review relating to remdesivir for the treatment of Covid-19 are being expedited.”

Remdesivir is among the existing drugs being broadly studied as potential Covid-19 treatments worldwide.

Meanwhile, Gilead temporarily halted emergency access to remdesivir due to rising demand.